Effect of Isavuconazole on the Pharmacokinetics of Sunitinib and Its Mechanism

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Sep 11

PMID 39261851

Authors

Jinyu Hu

Hailun Xia

Xiaohai Chen

Xinhao Xu

Hua-Lu Wu

Yuxin Shen

Ren-Ai Xu

Wenzhi Wu

Affiliations

Soon will be listed here.

Abstract

Background: Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC). Examining the mechanism underlying the interaction between sunitinib and isavuconazole was the aim of this effort.

Methods: The concentrations of sunitinib and its primary metabolite, N-desethyl sunitinib, were analyzed and quantified using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Our study evaluated the potential interaction between isavuconazole and sunitinib using rat liver microsomes (RLM), human liver microsomes (HLM), and in vivo rat models. For the in vivo study, two groups (n = 5) of Sprague-Dawley (SD) rats were randomly allocated to receive sunitinib either with or without co-administration of isavuconazole. Additionally, the effects of isavuconazole on the metabolic stability of sunitinib and N-desethyl sunitinib were studied in RLM in vitro.

Results: Our findings demonstrated that in RLM, isavuconazole exhibited a mixed non-competitive and competitive inhibition mechanism, with an IC (half maximal inhibitory concentration) value of 1.33 µM. Meanwhile, in HLM, isavuconazole demonstrated a competitive inhibition mechanism, with an IC of 5.30 µM. In vivo studies showed that the presence of isavuconazole significantly increased the pharmacokinetic characteristics of sunitinib, with the AUC, AUC, and T rising to approximately 211.38%, 203.92%, and 288.89%, respectively, in contrast to the control group (5 mg/kg sunitinib alone). The pharmacokinetic characteristics of the metabolite N-desethyl sunitinib in the presence of isavuconazole remained largely unchanged compared to the control group. Furthermore, in vitro metabolic stability experiments revealed that isavuconazole inhibited the metabolic processing of both sunitinib and N-desethyl sunitinib.

Conclusions: Isavuconazole had a major impact on sunitinib metabolism, providing fundamental information for the precise therapeutic administration of sunitinib.

References

Gabbia D, Dalla Pozza A, Albertoni L, Lazzari R, Zigiotto G, Carrara M . Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World J Gastroenterol. 2017; 23(42):7519-7530. PMC: 5698245. DOI: 10.3748/wjg.v23.i42.7519. View

Ananda-Rajah M, Kontoyiannis D . Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol. 2015; 10(5):693-708. DOI: 10.2217/fmb.15.34. View

Mahdi A, Wernly B, Pernow J, Zhou Z . Sunitinib and its effect in the cardiovascular system. Drug Discov Today. 2021; 26(8):1773-1775. DOI: 10.1016/j.drudis.2021.05.003. View

Nelson D, Kamataki T, Waxman D, Guengerich F, Estabrook R, Feyereisen R . The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12(1):1-51. DOI: 10.1089/dna.1993.12.1. View

Yuan X, Lu H, Zhao A, Ding Y, Min Q, Wang R . Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia. Drug Metab Rev. 2020; 52(2):225-234. DOI: 10.1080/03602532.2020.1733004. View

Peng Y, Dong S, Song Y, Hou D, Wang L, Li B . Key sunitinib-related biomarkers for renal cell carcinoma. Cancer Med. 2021; 10(19):6917-6930. PMC: 8495283. DOI: 10.1002/cam4.4206. View

Wang J, Cui X, Cheng C, Wang Y, Sun W, Huang C . Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats. Chem Biol Interact. 2021; 338:109426. DOI: 10.1016/j.cbi.2021.109426. View

Xu R, Li Q, Gao N, Wang J, Li X, Ye F . Effect of flavonoids and CYP3A4 variants on midostaurin metabolism. Food Chem Toxicol. 2023; 174:113669. DOI: 10.1016/j.fct.2023.113669. View

Mendel D, Laird A, Xin X, Louie S, Christensen J, Li G . In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9(1):327-37. View

10.

Kontoyiannis D, Marr K, Park B, Alexander B, Anaissie E, Walsh T . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010; 50(8):1091-100. DOI: 10.1086/651263. View

11.

DeWolf S, Laracy J, Perales M, Kamboj M, van den Brink M, Vardhana S . SARS-CoV-2 in immunocompromised individuals. Immunity. 2022; 55(10):1779-1798. PMC: 9468314. DOI: 10.1016/j.immuni.2022.09.006. View

12.

Ellsworth M, Ostrosky-Zeichner L . Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. J Fungi (Basel). 2020; 6(4). PMC: 7712939. DOI: 10.3390/jof6040324. View

13.

Shang H, Wang Z, Ma H, Sun Y, Ci X, Gu Y . Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. Pharm Biol. 2021; 59(1):200-208. PMC: 7894426. DOI: 10.1080/13880209.2021.1871634. View

14.

Ruan L, Fan L, Wang K, Zhang W, Wang X, Qiu X . The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS. Front Pharmacol. 2021; 12:749169. PMC: 8666568. DOI: 10.3389/fphar.2021.749169. View

15.

Wang Z, Sun W, Huang C, Wang L, Xia M, Cui X . Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm. 2014; 41(4):613-6. DOI: 10.3109/03639045.2014.886697. View

16.

Numakura K, Fujiyama N, Takahashi M, Igarashi R, Tsuruta H, Maeno A . Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget. 2018; 9(38):25277-25284. PMC: 5982748. DOI: 10.18632/oncotarget.25423. View

17.

Cornely O, Mullane K, Ostrosky-Zeichner L, Maher R, Croos-Dabrera R, Lu Q . Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018; 61(8):518-533. DOI: 10.1111/myc.12778. View

18.

Pan Y, Lu X, Shu G, Cen J, Lu J, Zhou M . Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma. Cancer Res. 2022; 83(1):103-116. PMC: 9811158. DOI: 10.1158/0008-5472.CAN-21-3432. View

19.

Daly A . Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006; 45(1):13-31. DOI: 10.2165/00003088-200645010-00002. View

20.

Stresser D, Mao J, Kenny J, Jones B, Grime K . Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert Opin Drug Metab Toxicol. 2013; 10(2):157-74. DOI: 10.1517/17425255.2014.856882. View